11:30 AM Proteinuria: A Key Endpoint in Rare Glomerular Diseases
Time: 11:30 am
day: Conference Day 1
Details:
In recent years, proteinuria has become regulatory approvable endpoint for new therapeutics for rare glomerular diseases and considerations for drug developers include:
- Considerations of measuring urinary albumin vs. total protein
- Timed 24-hour proteinuria or albuminuria excretion vs. spot urinary protein-to-creatine ratio
- Implications of varying recommendations in KDIGO and other nephrology practice guidelines
